Dashboard MRSA
Repurposing candidates for MRSA
Methicillin-resistant Staphylococcus aureus
Approved medicines with AI-predicted activity ≥40% against MRSA, leaving out medicines that are already antimicrobials. Each is shown with what it is already used for. They are surfaced computationally for further investigation, not as treatments.
- AI-predicted activity ≥40%
- 860
- Existing antimicrobials set aside
- 117
- Needing review
- 72
- Repurposing candidates
- 671
Repurposing candidates for MRSA
AI prediction · nothing measuredAll 671 repurposing candidates for MRSA.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- InavolisibExisting use: Breast cancer, Breast neoplasm51.0% AI-predicted activityagainst MRSA36 registered studies
- ApalutamideExisting use: Cancer, Metastatic prostate cancer, Neoplasm and 3 more51.0% AI-predicted activityagainst MRSA50+ registered studies
- OxazepamExisting use: Agitation, Anxiety, Anxiety disorder51.0% AI-predicted activityagainst MRSA14 registered studies
- Hydrocortisone ProbutateExisting use: Adrenal gland disease, Adrenocortical insufficiency, Allergic conjunctivitis and 32 more50.9% AI-predicted activityagainst MRSA50+ registered studies
- Estradiol ValerateExisting use: Atrophic Vaginitis, Atrophy, Breast cancer and 11 more50.9% AI-predicted activityagainst MRSA50+ registered studies
- VibegronExisting use: Overactive bladder, Polyuria, Urgency urinary incontinence and 1 more50.9% AI-predicted activityagainst MRSA16 registered studies
- MidostaurinExisting use: Acute myeloid leukemia, Mast-cell leukemia, Mastocytosis and 2 more50.9% AI-predicted activityagainst MRSA50+ registered studies
- Halofantrine HydrochlorideExisting use: Malaria50.8% AI-predicted activityagainst MRSA50+ registered studies
- FlunisolideExisting use: Airway obstruction, Asthma, Nasal congestion and 1 more50.8% AI-predicted activityagainst MRSA6 registered studies
- Pitavastatin SodiumExisting use: Abnormal circulating lipid concentration, Cardiovascular disease, Familial hypercholesterolemia and 2 more50.8% AI-predicted activityagainst MRSA18 registered studies
- TadalafilExisting use: Benign prostatic hyperplasia, Erectile dysfunction, Impotence and 2 more50.8% AI-predicted activityagainst MRSA50+ registered studies
- Pancuronium BromideExisting use: Other quaternary ammonium compounds50.6% AI-predicted activityagainst MRSA7 registered studies
- Pramipexole DihydrochlorideExisting use: Parkinson disease, Restless legs syndrome50.6% AI-predicted activityagainst MRSA50+ registered studies
- MoxidectinExisting use: Helminthiasis, Onchocerciasis50.6% AI-predicted activityagainst MRSA25 registered studies
- TelmisartanExisting use: Cardiovascular disease, Diabetes mellitus, Hypertension and 2 more50.6% AI-predicted activityagainst MRSA50+ registered studies
- NabiloneExisting use: Cancer, Nausea, Nausea and vomiting and 1 more50.5% AI-predicted activityagainst MRSA35 registered studies
- HydrocortisoneExisting use: Adrenal gland disease, Adrenocortical insufficiency, Allergic conjunctivitis and 32 more50.5% AI-predicted activityagainst MRSA50+ registered studies
- Alclometasone DipropionateExisting use: Eye inflammation, Skin disease50.4% AI-predicted activityagainst MRSA2 registered studies
- EstazolamExisting use: Insomnia50.4% AI-predicted activityagainst MRSA12 registered studies
- Rucaparib CamsylateExisting use: Cancer, Neoplasm, Ovarian cancer and 2 more50.3% AI-predicted activityagainst MRSA7 registered studies
- Alfuzosin HydrochlorideExisting use: Benign prostatic hyperplasia50.3% AI-predicted activityagainst MRSA50+ registered studies
- EtelcalcetideExisting use: Parathyroid disease, Secondary hyperparathyroidism50.3% AI-predicted activityagainst MRSA23 registered studies
- MitomycinExisting use: Adenocarcinoma, Cancer, Glaucoma and 1 more50.3% AI-predicted activityagainst MRSA50+ registered studies
- Iptacopan HydrochlorideExisting use: Acquired paroxysmal nocturnal hemoglobinuria, IGA glomerulonephritis, Paroxysmal nocturnal hemoglobinuria50.3% AI-predicted activityagainst MRSA1 registered study